Insight, China's Pharmaceutical Industry

GenScript’s ProBio Secures RMB 479.7 M License Payment for LM‑299, Boosting SinoBiopharmaceutical’s Portfolio

GenScript Biotech Corporation (HKG: 1548) today announced that its Contract‑Development‑and‑Manufacturing‑Organization (CDMO) platform, ProBio, received a...

Company Deals Drug

Chengdu Olymvax Biopharmaceuticals & Delonix Bioworks Announce Joint Development of Gene‑Engineered Pertussis Vaccine

Fineline Cube Oct 15, 2025

Chengdu Olymvax Biopharmaceuticals Inc. and Delonix Bioworks Co., Ltd. today announced a strategic collaboration and...

Company Deals Drug

Jiudian Pharma Acquires Chengdu Peide’s JIJ02 Gel, Advancing a Novel Acne Treatment into Phase 1

Fineline Cube Oct 15, 2025

Hunan Jiudian Pharmaceutical Co., Ltd. (SHE: 300705) today announced the acquisition of all developed results...

Company

Junshi Biosciences Reports 49 % YoY Revenue Growth in H1 2025, Raises Cash Reserves to RMB 3.49 B

Fineline Cube Oct 15, 2025

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) today released its 2025 interim financial...

Company

Johnson & Johnson Reports Robust Q3 2025 Sales Growth, Boosts Full‑Year Outlook

Fineline Cube Oct 15, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced its third‑quarter results for 2025, showing a 5.4 %...

Company Deals

Kailera Therapeutics Secures $600 Million Series B Funding from Bain Capital Private Equity to Accelerate Global Obesity Pipeline

Fineline Cube Oct 15, 2025

Kailera Therapeutics, Inc., the Delaware‑registered spin‑off of Hengrui Pharma, today announced the closing of a...

Company Deals Drug

Bio‑Thera Expands Canadian Partnership with Intas Pharma for Golimumab Biosimilar BAT2506

Fineline Cube Oct 15, 2025

Bio‑Thera Solutions (SHA: 688177) today announced the expansion of its collaboration with Intas Pharmaceuticals for...

Policy / Regulatory

National Joint Procurement Office Announces 11th Round VBP, AstraZeneca Dapagliflozin Leads Demand

Fineline Cube Oct 15, 2025

On October 11, 2025, the National Joint Procurement Office (NJPO) released the full company list for...

Company Drug

Maxvax Biotech Secures NMPA Acceptance for Its Recombinant Herpes Zoster Vaccine

Fineline Cube Oct 15, 2025

Maxvax Biotech announced today that the China National Medical Products Administration (NMPA) has accepted the...

Company Deals

Shandong Buchang Names Goodfellow as Exclusive Philippine Distributor for Efparepoetin Alfa to Treat CKD Anemia

Fineline Cube Oct 15, 2025

Shandong Shandong Buchang Names Goodfellow as Exclusive Philippine Distributor for Efparepoetin Alfa to Treat CKD Anemia Co., Ltd....

Company Deals

Zhaoke Ophthalmology Secures Exclusive Indonesian Distribution Deal for NVK002, a Novel Atropine‑Based Myopia Treatment

Fineline Cube Oct 15, 2025

Zhaoke Ophthalmology Limited (HKG: 6622), a leading China‑based ocular therapeutics company, announced today that it...

Company Drug

CSPC Pharmaceutical Group Announces NMPA Acceptance of Efmedaglutide Alfa Injection for Long‑Term Weight Management

Fineline Cube Oct 14, 2025

CSPC Pharmaceutical Group Limited (HKG: 1093) today announced that the National Medical Products Administration (NMPA)...

Company Drug

UCB Biosciences Receives NMPA Marketing Authorization for Zilucoplan (Zilbrysq) in Adult Generalized Myasthenia Gravis

Fineline Cube Oct 14, 2025

UCB S.A. (EBR: UCB), a global biopharmaceutical company, announced today that the National Medical Products...

Company Drug

Mabwell Bioscience Receives NMPA IND Approval for 7MW4911 CDH17‑Targeting ADC in Advanced Solid Tumors

Fineline Cube Oct 14, 2025

Mabwell Bioscience (SHA: 688062) announced today that the National Medical Products Administration (NMPA) has granted...

Company Drug

GSK Receives China NMPA Approval for Shingrix in Immunocompromised Adults

Fineline Cube Oct 14, 2025

GlaxoSmithKline (NYSE: GSK) announced today that the Chinese National Medical Products Administration (NMPA) has granted approval...

Company Drug

Arcutis Biotherapeutics Receives FDA Approval for ZORYVE (Roflumilast) Cream in Children 2‑5 Years with Atopic Dermatitis

Fineline Cube Oct 14, 2025

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), the U.S. partner of Huadong Medicine Co., Ltd. (SHE: 000963), announced today that...

Company Drug

BeOne Medicines Receives FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed Mantle Cell Lymphoma

Fineline Cube Oct 14, 2025

BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that the U.S. Food...

Company Drug

ReviR Therapeutics Secures FDA Orphan Drug Designation for RTX‑117, Targeting Charcot‑Marie‑Tooth Disease

Fineline Cube Oct 14, 2025

ReviR Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan...

Company Drug

Everest Medicines Commences Global Phase I Trial of Universal mRNA Cancer Vaccine EVM14

Fineline Cube Oct 14, 2025

Everest Medicines Limited (HKG: 1952) announced today that the first patient has been successfully dosed...

Company Deals Drug

Boehringer Ingelheim Launches Trajenta Production in Zhangjiang, China

Fineline Cube Oct 14, 2025

Boehringer Ingelheim (BI) announced today the official start‑up of its local manufacturing plan for the diabetes...

Insight, China's Pharmaceutical Industry

D3 Bio Closes $108 M Series B to Advance Elisrasib KRAS G12C Phase 3 Trials Globally

Fosun Pharma Licenses Oral GLP‑1R Agonist YP05002 to Pfizer in $2.1 Billion Deal

Shandong Boan Licenses US Rights for Denosumab Biosimilars to Nanjing Kingfriend in $75 Million Deal

Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development

Lee’s Pharm Staccato-OBT Acquisition Bolsters UCB Partnership

Innovent’s PECONDLE Meets Phase 3 IL‑23 Psoriasis Endpoints with Quarterly Dosing

Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti‑EGFR Antibody in Colorectal Cancer

GenScript’s ProBio Secures RMB 479.7 M License Payment for LM‑299, Boosting SinoBiopharmaceutical’s Portfolio

Chengdu Olymvax Biopharmaceuticals & Delonix Bioworks Announce Joint Development of Gene‑Engineered Pertussis Vaccine

Jiudian Pharma Acquires Chengdu Peide’s JIJ02 Gel, Advancing a Novel Acne Treatment into Phase 1

Junshi Biosciences Reports 49 % YoY Revenue Growth in H1 2025, Raises Cash Reserves to RMB 3.49 B

Johnson & Johnson Reports Robust Q3 2025 Sales Growth, Boosts Full‑Year Outlook

Kailera Therapeutics Secures $600 Million Series B Funding from Bain Capital Private Equity to Accelerate Global Obesity Pipeline

Bio‑Thera Expands Canadian Partnership with Intas Pharma for Golimumab Biosimilar BAT2506

National Joint Procurement Office Announces 11th Round VBP, AstraZeneca Dapagliflozin Leads Demand

Maxvax Biotech Secures NMPA Acceptance for Its Recombinant Herpes Zoster Vaccine

Shandong Buchang Names Goodfellow as Exclusive Philippine Distributor for Efparepoetin Alfa to Treat CKD Anemia

Zhaoke Ophthalmology Secures Exclusive Indonesian Distribution Deal for NVK002, a Novel Atropine‑Based Myopia Treatment

CSPC Pharmaceutical Group Announces NMPA Acceptance of Efmedaglutide Alfa Injection for Long‑Term Weight Management

UCB Biosciences Receives NMPA Marketing Authorization for Zilucoplan (Zilbrysq) in Adult Generalized Myasthenia Gravis

Mabwell Bioscience Receives NMPA IND Approval for 7MW4911 CDH17‑Targeting ADC in Advanced Solid Tumors

GSK Receives China NMPA Approval for Shingrix in Immunocompromised Adults

Arcutis Biotherapeutics Receives FDA Approval for ZORYVE (Roflumilast) Cream in Children 2‑5 Years with Atopic Dermatitis

BeOne Medicines Receives FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed Mantle Cell Lymphoma

ReviR Therapeutics Secures FDA Orphan Drug Designation for RTX‑117, Targeting Charcot‑Marie‑Tooth Disease

Everest Medicines Commences Global Phase I Trial of Universal mRNA Cancer Vaccine EVM14

Boehringer Ingelheim Launches Trajenta Production in Zhangjiang, China

You Missed

Innovent’s PECONDLE Meets Phase 3 IL‑23 Psoriasis Endpoints with Quarterly Dosing

D3 Bio Closes $108 M Series B to Advance Elisrasib KRAS G12C Phase 3 Trials Globally

Fosun Pharma Licenses Oral GLP‑1R Agonist YP05002 to Pfizer in $2.1 Billion Deal

Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti‑EGFR Antibody in Colorectal Cancer